A review. Advax has been shown to enhance the immunogenicity of a broad range of antigens including whole inactivated viruses, recombinant proteins, synthetic peptides, toxins, and venoms. It is effective in a broad range of animal species and is safe and well tolerated when administered during pregnancy and early neonatal life. It acts synergistically with traditional innate immune activators such as murabutide or CpG oligonucleotides. Pos. results in preclin. studies have translated into successful human clin. trials, which have confirmed its exceptional safety, tolerability, and efficacy. Advax could be ideal for use in pediatric vaccines and vaccines for pregnant women. When formulated with SARS coronavirus vaccine, Advax reduced the risk of lung eosinophilic immunopathol., suggesting that it may be beneficial for use in respiratory virus vaccines, e.g., against SARS, Middle East respiratory syndrome and respiratory syncytial virus, where the risk of vaccine-enhanced lung immunopathol. is a major concern. Its ability to induce high numbers of antigen-specific IFN-y-producing T cells also makes Advax well suited for use in vaccines against intracellular pathogens, such as Listeria or Mycobacterium tuberculosis.